Chandar Abboy, MD
Critical Care Medicine · Fayetteville, NCNPI 1275583585
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,826 of the $12,663 with a category attached, or 85.5%. Eli Lilly accounts for 93.1% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $11,901, more than ten times the $640 reported in 2019. Among critical care medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 68 payments — averaging $186.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$12K
- Sunovion Pharmaceuticals Inc.$88
- Actelion Pharmaceuticals US, Inc.$76
- Merck$66
- GSK$66
- AstraZeneca$65
- plus $512 from 15 others
Across 180 payments — averaging $26,491 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.3M
- Sanofi US Services Inc.$2M
- GSK$257K
- Hikma Pharmaceuticals USA$91K
- AstraZeneca$69K
- Cipla USA Inc.$41K
- plus $50K from 6 others
What the payments were for
- Travel & lodging$1,78614%
- Food & beverage$10,82685%
- Education$510%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 18 | $11,790 |
| Sunovion Pharmaceuticals Inc. | 8 | $88 |
| Actelion Pharmaceuticals US, Inc. | 4 | $76 |
| Merck | 3 | $66 |
| GSK | 5 | $66 |
| AstraZeneca | 4 | $65 |
| Regeneron Healthcare Solutions, Inc. | 3 | $64 |
| Boehringer Ingelheim | 4 | $60 |
| Abiomed | 1 | $60 |
| Philips North America LLC | 3 | $53 |
| Grifols USA, LLC | 2 | $37 |
| Mylan Specialty L.p. | 2 | $34 |
| Electromed, Inc. | 2 | $34 |
| Getinge USA Sales, LLC | 1 | $33 |
| Genentech USA, Inc. | 2 | $33 |
| Body Vision Medical Inc. | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $21 |
| Resmed Corp | 1 | $17 |
| AbbVie | 1 | $17 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $15 |
| Insmed, Inc. | 1 | $12 |
How this compares
$12,663 in reported general payments places this provider in the 90th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other critical care medicine in Fayetteville
- Alexis SmithHuntersville$726K
- Rabih BecharaCharlotte$453K
- Ashish KhannaWinston Salem$364K
- Alan HeffnerCharlotte$326K
- Daniel FeinsteinPinehurst$213K
- Daniel FoxRaleigh$133K
- Hassan YousafWinston Salem$97K
- Neil MacintyreDurham$70K
- Andrea MacdonaldRaleigh$67K
- John DotyCharlotte$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.